New Developments in Fertility Treatment

One of the more challenging aspects of in vitro fertilization (IVF) might soon become easier for women undergoing the procedure.

Each year, many women across the nation experience IVF, which involves a strenuous process of extracting eggs and fertilizing them in a lab. This method can be both physically and emotionally taxing.

Leading up to the egg retrieval, patients must administer hormone injections daily. Many describe it as one of the most taxing aspects of IVF.

Researchers at McGill University believe they may have found a solution to alleviate some of this stress.

They have created a light-activated microneedle patch designed to automatically deliver hormones at optimal times. This innovation could reduce discomfort and potentially enhance the chances of achieving a successful pregnancy.

According to Vivian Tam, the study’s lead researcher and a doctoral student, “The success rate of IVF is at best 30%, even for the youngest women.” In her published remarks, she expressed hope that removing the chance for human error from self-injections could improve these rates.

This innovative delivery system utilizes hydrogel microneedles that contain nanoparticles capable of storing the important IVF hormone leuprolide. These microneedles release the hormone when triggered by near-infrared light.

First, researchers figured out how many hormone-packed nanoparticles each microneedle could accommodate without losing its ability to penetrate the skin effectively.

Next, they tested whether light could consistently release the hormone over two hours using a pig skin model.

Ultimately, they confirmed that even brief light pulses—only five minutes long—could deliver significant amounts of leuprolide into the skin, bloodstream, and organs of living rats.

According to Tam, “The light can also be programmed to release the drug at specific times when it is needed, but this may differ from patient to patient.”

While phototriggered drug delivery isn’t a novel idea, previous attempts have faced major challenges. Past methods often released unwanted substances into the body, which poses safety and regulatory issues.

However, the McGill patch circumvents those problems effectively.

This breakthrough is notable since it marks the first successful demonstration of light-induced drug release from a nanoparticle-microneedle system without introducing foreign substances into the body, remarked Marta Cerruti, a materials engineering professor and co-author of the study.

The researchers believe that this advancement could make the technology a more feasible treatment option, potentially allowing for quicker clinical adoption than past designs.

This progress comes as the demand for IVF grows, driven by advancements in medical technology, greater awareness, and increased employer coverage.

Moreover, many couples are postponing childbearing, contributing to a rise in the popularity of IVF as a pathway to parenthood.

Recent statistics indicate that by 2023, 42% of adults in the U.S. report having experienced infertility treatments, up from 33% five years earlier.

Globally, the World Health Organization estimates there are over 2.5 million IVF cycles performed annually, leading to around 500,000 deliveries each year.

The researchers noted, “The prospect of experiencing a pain-free treatment could significantly transform the experience for patients needing regular drug administration via injections.” However, they emphasize that this technology isn’t exclusive to IVF; it could potentially benefit anyone needing daily injections, such as diabetes or multiple sclerosis patients.

Looking ahead, they aim to enhance the system’s dosage and explore its commercial viability.